Evvy Raises $40M Series B to Scale Vaginal Microbiome Testing Into Fertility Care
Evvy has raised a $40 million Series B led by Catalio Capital Management. The company announced the round on Tuesday, September 15, 2026. TechCrunch
Evvy was launched in 2021 by Priyanka Jain, Laine Bruzek and Pita Navarro. Jain serves as chief executive. The company says it now serves more than 100,000 patients across the United States and works with 3,000 practitioners.
Evvy describes its core product as an at-home test using metagenomic next-generation sequencing, or mNGS, to characterize vaginal microbes from a single swab. The company touts the assay as CLIA-certified and CLEP-certified. Evvy says the test detects more than 700 bacteria and fungi, with every result reviewed by a licensed clinician and paired with a customized plan that can include targeted prescriptions where eligible. The company also offers a membership to track how treatments and behaviors affect the vaginal microbiome over time. Evvy
Catalio Capital Management, a New York-based investment firm focused on healthcare investing across private, public and credit markets, led the financing. The Series B added new investors including the U.S. Fertility Innovation Fund, Rethink Impact and Muse Capital. SiliconANGLE
Evvy plans to expand its vaginal microbiome platform into reproductive healthcare, starting with fertility and IVF. The company aims to make vaginal microbiome testing routine. Beauty Independent
That clinical expansion is paired with a research program built on the same sequencing infrastructure. Evvy says it has generated 15 peer-reviewed publications and abstracts. It says it has identified novel bacterial vaginosis subtypes and discovered hundreds of previously uncatalogued vaginal microbiome genomes.
On the product side, Evvy in May started offering an AI assistant called EvvyAI, billed as an advisor for vaginal health. It has also launched a prospective study leveraging its vaginal microbiome tests in IVF clinics.
The broader context here is familiar to anyone who has watched diagnostics companies try to move beyond one-test economics. A single at-home swab can start a relationship. Longitudinal sampling, clinician review and prescription pathways sustain it. Research output then compounds the value of each new sample.
Looking at what this means for fertility workflows, the IVF focus is pragmatic. Clinics already run structured protocols with measurable endpoints. Adding microbiome sequencing into that loop creates dense, time-bound data. It also puts Evvy inside a referral channel with motivated patients and specialist oversight, rather than relying solely on direct-to-consumer acquisition.
In my view, the interesting technical bet is not mNGS sensitivity alone but the combination of sequencing depth with an AI interface and human clinical review. Automated guidance lowers friction for patients navigating recurrent symptoms. Clinician oversight constrains it. Whether that balance scales across thousands of practitioners will depend on integration work that rarely makes funding announcements, including EHR fit, result interpretability and clear escalation paths. If Evvy gets that right, routine microbiome testing becomes standard input rather than specialty add-on, and that would give clinicians higher-resolution data for conditions long managed with blunt tools.
